Abstract:We read with interest the study by Lin et al1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar that reported a high rate of false-positive diagnoses of small bowel bacterial overgrowth (SBBO) by glucose hydrogen breath testing (HBT) with nearly 50% of diagnoses being false-positives caused by rapid transit and early colonic fermentation of unabsorbed substrate. This effect was most marked in patients with previous upper gastrointestinal surgery (65% vs 13% in patients without prior surgery). Lactulose is a poorly absorbed, fermentable disaccharide that has also been used to detect SBBO by HBT. The lactulose HBT is said to be more sensitive than glucose HBT or bacterial culture of jejunal aspirates (the “reference standard”) because it can detect cases with distal SBBO and pathologic bacterial strains that do not culture well.2Schiller L.R. Curr Gastroenterol Rep. 2007; 9: 373-377Crossref PubMed Scopus (32) Google Scholar Unfortunately, clinical studies have also shown that lactulose HBT does not provide a reliable diagnosis of SBBO because of variability in orocecal transit time.1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar, 3Corazza G.R. et al.Gastroenterology. 1990; 98: 302-309Abstract Full Text PDF PubMed Google Scholar, 4Yu D. et al.Gut. 2011; 60: 334-340Crossref PubMed Scopus (202) Google Scholar To address this limitation, investigators have combined lactulose HBT with concurrent scintigraphic assessment of orocecal transit. The diagnosis of SBBO is confirmed if there is a physiologically relevant increase in breath hydrogen well before labeled substrate enters the caecum. Using this approach, Zhao et al5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar found that the combined test identified SBBO in at least 1 in 3 patients with irritable bowel syndrome (IBS) and also that the presence of bacteria in the small bowel was associated with increased risk of lactose intolerance in a population with lactase deficiency. Consistent with the findings of Lin et al,1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar the orocecal transit time was similar in those with and without SBBO (63 min vs 56 min; P = .071).5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar Moreover there was no difference in orocecal transit time between patients with IBS and healthy control subjects (74 min vs 68 min; P = .433).5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar Thus, it was only the presence of abnormal findings on combined lactulose HBT and scinitigraphy that identified possible SIBO in the patients with IBS. Subsequently, a prospective study by the same group demonstrated that the results of the combined test can also guide therapy. Beneficial effects of antibiotic treatment (rifaximin) on IBS symptoms were observed more often in SBBO-positive than SBBO-negative patients (64% vs 15%; P = .018).6Zhao J. et al.Neurogastroenterol Motil. 2014; 26: 794-802Crossref PubMed Scopus (50) Google Scholar In particular, patients with IBS with diarrhea and SBBO frequently reported improvement in abdominal symptoms including stool frequency and consistency.6Zhao J. et al.Neurogastroenterol Motil. 2014; 26: 794-802Crossref PubMed Scopus (50) Google Scholar Taken together, as argued by Sellin7Sellin J.H. Clin Gastroenterol Hepatol. 2016; 14: 209-211Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar in his editorial, these findings suggest that lactulose HBT with concurrent scintigraphy provides an accurate diagnostic test for SBBO. If this is not available routinely for reasons of cost, then patients with abnormal results from glucose or lactulose HBT should be considered for a confirmatory test with concurrent scintigraphy to distinguish SBBO from rapid transit accompanied by early colonic fermentation. The use of serial tests (ie, HBT followed by scintigraphy) may be less ideal because of relatively high day-to-day variation in orocecal transit time. Looking ahead, the results of the combined lactulose HBT with concurrent scintigraphy investigation may help to identify the causes of IBS symptoms and to direct antibiotic therapy to patients that are likely to benefit. This would be welcome because the number needed to treat was >10 in unselected patients with IBS given rifaximin in the TARGET study.8Pimentel M. et al.Dig Dis Sci. 2011; 56: 2067-2072Crossref PubMed Scopus (76) Google Scholar If the outcome data of Zhao et al were confirmed, the proposed approach could reduce this to a number needed to treat of ∼3–4 and, at the same time, reduce the unnecessary and ineffective use of antibiotics in patients with IBS without SBBO. Scintigraphy Demonstrates High Rate of False-positive Results From Glucose Breath Tests for Small Bowel Bacterial OvergrowthClinical Gastroenterology and HepatologyVol. 14Issue 2PreviewBreath tests for hydrogen and/or methane are used to detect small bowel bacterial overgrowth (SBBO), but false-positive results can arise from clinical conditions that accelerate small bowel transit and deliver unabsorbed glucose to the colon. We investigated the prevalence of false-positive results from glucose breath tests by also evaluating patients with scintigraphy. Full-Text PDF ReplyClinical Gastroenterology and HepatologyVol. 14Issue 10PreviewThe comments by Deng et al on recent literature point out the necessity of using concurrent scintigraphic assessment of orocecal transit time when attempting to attribute increases in breath hydrogen or methane levels after lactulose ingestion to small-bowel bacterial overgrowth. We agree, but want to emphasize the importance of the scintigraphy protocol used to avoid a false diagnosis of bacterial overgrowth. In the studies cited by Deng et al, the goal was to distinguish, from among groups of patients with putative irritable bowel syndrome or lactase deficiency, patients whose symptoms might result from bacterial overgrowth. Full-Text PDF

A Rapid and Reliable Spectrofluorimetric Method to Measure the Urinary Lactulose/Mannitol Ratio for Dysbiosis Assessment

Clinical Value of Radionuclide Small Intestine Transit Time Measurement Combined with Lactulose Hydrogen Breath Test for the Diagnosis of Bacterial Overgrowth in Irritable Bowel Syndrome.

Four-sample Lactose Hydrogen Breath Test for Diagnosis of Lactose Malabsorption in Irritable Bowel Syndrome Patients with Diarrhea

Fecal Metabolite Quantitation for Rapid Assessment of the Gut Microbiome

Hydrogen Breath Testing with Measurement of Orocecal Transit for Diagnosis of Small Bowel Bacterial Overgrowth.

A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.

Su2034 Diagnosis of Small Intestinal Bacterial Overgrowth by Lactulose Hydrogen Breath Test with Scintigraphic Oro-Caecal Transit Test: Methodological Validation of Diagnostic Criteria in Healthy Controls and Patients with Diarrhea Predominant Irritable Bowel Syndrome

Quantification of Gut Microbiota Dysbiosis-Related Organic Acids in Human Urine Using LC-MS/MS

A New Biomarker Profiling Strategy for Gut Microbiome Research: Valid Association of Metabolites to Metabolism of Microbiota Detected by Non-Targeted Metabolomics in Human Urine

Rapid simultaneous determination of gut microbial phenylalanine, tyrosine, and tryptophan metabolites in rat serum, urine, and faeces using LC-MS/MS and its application to a type 2 diabetes mellitus study

Lactose Breath Test: Possible Strategies to Optimize Test Performance, Accuracy, and Clinical Impact

A Simple Method for Rapid Screening and Diagnosis of Common Organic Acidemias: Quantitative Detection of Serum and Urine Organic Acid Profiles Based on Liquid Chromatography-Tandem Mass Spectrometry

Development of a rapid simultaneous assay of two urinary tetrasaccharide metabolites using differential ion mobility and tandem mass spectrometry and its application to patients with glycogen storage disease (type Ib and II)

The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients

Simple, high-throughput measurement of gut-derived short-chain fatty acids in clinically relevant biofluids using gas chromatography-mass spectrometry

Simutaneous Determination of Lactulose, Mannitol and Lactose in Urine with Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method

Development of a fast and cost-effective gas chromatography–mass spectrometry method for the quantification of short-chain and medium-chain fatty acids in human biofluids

Development and application of a multi-sugar assay to assess intestinal permeability

Rapid LA-REIMS and comprehensive UHPLC-HRMS for metabolic phenotyping of feces

Su2051 – Intracolic Molecular Ultrasound Imaging for Non-Invasive and Quantitative Assessment of Tumor Necrosis Factor-α Expression in Inflammatory Bowel Disease

Performance equivalence and validation of a rapid microbiological method for detection and quantification of yeast and mold in an antacid oral suspension